PREVENT DIABETES Act
Sponsor
Full profile: /officials/D000197
Source: Congress.gov · FEC
Cosponsors (9)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-24
Source: Congress.gov
Committee Activity
Currently in
- House Committee on Energy and CommerceReferred To · 2025-02-24
- House Committee on Ways and MeansReferred To · 2025-02-24
Plain-English Summary
Promoting Responsible and Effective Virtual Experiences through Novel Technology to Deliver Improved Access and Better Engagement with Tested and Evidence-based Strategies Act or the PREVENT DIABETES Act This bill allows health care entities to provide virtual services under the Medicare Diabetes Prevention Program for an additional three years. The Medicare Diabetes Prevention Program offers Medicare beneficiaries who are at risk of developing Type 2 diabetes specialized training and education regarding diet, exercise, and other behavioral changes. The Centers for Medicare & Medicaid Services issued temporary authorization for entities participating in the program to provide these services virtually until December 31, 2027. The bill extends the authorization for virtual services until December 31, 2030.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Subjects
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- HR3491DeOndra Dixon INCLUDE Project Act of 2025Reported by Committee · 2026-07-02
- HR9392Medicare Advantage Cost Transparency ActReferred to Committee · 2026-06-25
- HRES1285Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.Referred to Committee · 2026-05-14
- HR8432To provide the Food and Drug Administration needed authorities to carry out its regulatory mission with respect to human foods, to provide additional resources and authorities with respect to human foods research, and for other purposes.Referred to Committee · 2026-04-22